Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103376 · ClinicalTrials.gov registry record · Phase 2
Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer
A Phase 2 study, sponsored by Medical University of South Carolina.
- Terminated
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00103376: Clinical Trial Phase 2 study, sponsored by Medical University of South Carolina.
NCT00103376 is a Phase 2 study that was terminated before completion, run by Medical University of South Carolina. The registered enrollment target is 23 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00103376, a Phase 2 study, was terminated before completion, sponsored by Medical University of South Carolina.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Androgens can cause the growth of prostate cancer cells. Drugs, such as goserelin, leuprolide, flutamide, or bicalutamide, may stop the adrenal glands from making androgens. Giving bortezomib with hormone therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving bortezomib with or without hormone therapy works in treating patients with relapsed prostate cancer.
Interventions
- DRUG Velcade
- DRUG LH-RH Agonist
- DRUG Androgen Receptor Antagonists
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2004-10 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Why NCT00103376 stopped before completion
NCT00103376 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 3 interventions - of which Velcade is the first listed.
NCT00103376 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00103376 about?
NCT00103376 is a clinical study titled "Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer". RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Androgens can cause the growth of prostate cancer cells. Drugs, such as goserelin, leuprolide, flutamide, or bicalutamide, may stop the adrenal glands from making androgens. Giving bortez...
What is the current status of trial NCT00103376?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2004-10. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00103376?
The interventions under investigation include: Velcade (DRUG), LH-RH Agonist (DRUG), Androgen Receptor Antagonists (DRUG).
Who is sponsoring clinical trial NCT00103376?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00103376's enrollment target sits among peer trials
23 1784th of 2000 higher than 211 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia